欧洲肌肉减少症治疗市场预测至 2030 年 - 区域分析 - 按治疗类型(维生素 D 和钙补充剂、蛋白质补充剂、维生素 B12 补充剂等)和分销渠道(药店、零售渠道、在线渠道等)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 78    |    Report Code: BMIRE00030430    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Sarcopenia Treatment Market
2022 年欧洲肌肉减少症治疗市场价值为 9.9346 亿美元,预计到 2030 年将达到 14.6781 亿美元;预计 2022 年至 2030 年的复合年增长率为 5.0%。

成人营养不良和维生素缺乏症的增加推动了欧洲肌肉减少症治疗市场的发展

营养不良是肌肉减少症的主要危险因素之一。根据世界卫生组织的数据,截至 2021 年,全球约有 23 亿成年人营养不良,占全球人口的近 30%。在报告的风险因素中,蛋白质能量缺乏是肌肉减少症的常见原因。此外,维生素 D 缺乏或不足与多种疾病的风险增加呈正相关,例如癌症、肥胖症、心血管疾病和肌肉减少症。根据美国国立卫生研究院 (NIH) 的数据,全球近 50% 的人口患有维生素 D 不足,约 10 亿人缺乏维生素 D。

欧洲肌肉减少症治疗市场概览

欧洲的肌肉减少症治疗市场分为德国、法国、英国、意大利、西班牙和欧洲其他地区。欧洲在全球肌肉减少症治疗市场中占有重要地位,预计在预测期内将实现显著的复合年增长率。

德国因其创新的医疗保健方法而成为一个具有吸引力的市场。根据联邦统计局的数据,2021 年该国的医疗支出为 4740 亿美元。德国老龄化社会对肌肉减少症和肌肉减少性肥胖 (SO) 的认识正在逐渐提高。在 70 岁及以上的德国男性中,肌肉减少症和 SO 相对少见 (<5%)。因此,骨科疾病病例的激增,再加上对营养补充剂的需求不断增长,推动了德国肌肉减少症治疗市场的增长。

欧洲肌肉减少症治疗市场收入及预测至 2030 年(百万美元)

欧洲肌肉减少症治疗市场细分

欧洲肌肉减少症治疗市场分为治疗类型、分销渠道和国家。

根据治疗类型,欧洲肌肉减少症治疗市场细分为维生素 D 和钙补充剂、蛋白质补充剂、维生素 B12 补充剂等。维生素 D 和钙补充剂部分在 2022 年占据了欧洲肌肉减少症治疗市场的最大份额。

在分销渠道方面,欧洲肌肉减少症治疗市场细分为药店、零售渠道、在线渠道和其他。 2022 年,药房部门占据了欧洲肌肉减少症治疗市场的最大份额。

按国家/地区划分,欧洲肌肉减少症治疗市场分为德国、法国、意大利、英国、西班牙和欧洲其他地区。2022 年,德国占据了欧洲肌肉减少症治疗市场的主导地位。

雅培实验室、安利公司、拜耳公司、葛兰素史克公司、Metagenics LLC、雀巢健康科学公司、诺华公司、辉瑞公司和赛诺菲公司是欧洲肌肉减少症治疗市场的一些领先公司。

Europe Sarcopenia Treatment Strategic Insights

Strategic insights for Europe Sarcopenia Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-sarcopenia-treatment-market-strategic-framework.webp
Get more information on this report

Europe Sarcopenia Treatment Report Scope

Report Attribute Details
Market size in 2022 US$ 993.46 Million
Market Size by 2030 US$ 1,467.81 Million
Global CAGR (2022 - 2030) 5.0%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 治疗类型
  • 维生素 D 和钙补充剂
  • 蛋白质补充剂
  • 维生素 B12 补充剂
By 分销渠道
  • 药店
  • 零售渠道
  • 在线渠道
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • Abbott Laboratories
  • Amway Corp
  • Bayer AG
  • GSK Plc
  • Metagenics LLC
  • Nestle Health Science SA
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Get more information on this report

    Europe Sarcopenia Treatment Regional Insights

    The regional scope of Europe Sarcopenia Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-sarcopenia-treatment-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Sarcopenia Treatment Market

    1. Abbott Laboratories 
    2. Amway Corp 
    3. Bayer AG 
    4. GSK Plc 
    5. Metagenics LLC 
    6. Nestle Health Science SA 
    7. Novartis AG 
    8. Pfizer Inc 
    9. Sanofi SA 

    Frequently Asked Questions
    How big is the Europe Sarcopenia Treatment Market?

    The Europe Sarcopenia Treatment Market is valued at US$ 993.46 Million in 2022, it is projected to reach US$ 1,467.81 Million by 2030.

    What is the CAGR for Europe Sarcopenia Treatment Market by (2022 - 2030)?

    As per our report Europe Sarcopenia Treatment Market, the market size is valued at US$ 993.46 Million in 2022, projecting it to reach US$ 1,467.81 Million by 2030. This translates to a CAGR of approximately 5.0% during the forecast period.

    What segments are covered in this report?

    The Europe Sarcopenia Treatment Market report typically cover these key segments-

  • 治疗类型 (维生素 D 和钙补充剂, 蛋白质补充剂, 维生素 B12 补充剂)
  • 分销渠道 (药店, 零售渠道, 在线渠道)
  • What is the historic period, base year, and forecast period taken for Europe Sarcopenia Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Sarcopenia Treatment Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Europe Sarcopenia Treatment Market?

    The Europe Sarcopenia Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Abbott Laboratories
  • Amway Corp
  • Bayer AG
  • GSK Plc
  • Metagenics LLC
  • Nestle Health Science SA
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Who should buy this report?

    The Europe Sarcopenia Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Sarcopenia Treatment Market value chain can benefit from the information contained in a comprehensive market report.